CARISOPRODOL Drug Interactions
Also known as: Carisoprodol
Carisoprodol is a muscle relaxant medication used to help relieve discomfort from acute, painful muscle and bone conditions in adults. It works by affecting communication between nerves in the central nervous system to help relax muscles. This medication is typically used for short periods, usually up to two or three weeks.CARISOPRODOL has 10 documented drug interactions in our database, including 0 contraindicated, 10 major, 0 moderate, and 0 minor interactions.
0
Contraindicated
10
Major
0
Moderate
0
Minor
Patients may experience profound sedation, respiratory depression, hypotension, and psychomotor impairment. This can lead to increased risk of falls, accidental injury, and potentially life-threatening respiratory arrest. The combination significantly impairs the ability to operate machinery or drive safely.
Mechanism
Buprenorphine, an opioid partial agonist, and carisoprodol, a centrally acting muscle relaxant, both exert central nervous system (CNS) depressant effects. This combination leads to an additive pharmacological effect on GABAergic and opioid receptors, enhancing CNS depression. Carisoprodol's active metabolite, meprobamate, also contributes significantly to this depressant effect.
Clinical Management
Avoid concomitant use of buprenorphine and carisoprodol due to the high risk of severe CNS and respiratory depression. If co-administration is unavoidable, initiate at the lowest effective doses, monitor patients closely for signs of sedation and respiratory depression, and consider alternative non-opioid pain management or non-benzodiazepine muscle relaxants. Educate patients on the risks and advise against driving or operating heavy machinery.
Patients may experience profound sedation, respiratory depression, hypotension, psychomotor impairment, and coma. This combination significantly increases the risk of accidental overdose, life-threatening respiratory arrest, and death. Impaired motor coordination can also increase the risk of falls and accidents.
Mechanism
Both fentanyl, an opioid agonist, and carisoprodol, a centrally acting muscle relaxant, exert depressant effects on the central nervous system (CNS). Carisoprodol is metabolized to meprobamate, which also possesses significant CNS depressant and anxiolytic properties. The co-administration leads to an additive pharmacological effect, enhancing CNS depression.
Clinical Management
Avoid concomitant use of fentanyl and carisoprodol whenever possible. If co-administration is unavoidable, reduce the dose of one or both drugs, initiate at the lowest effective dose, and monitor patients closely for signs of respiratory depression, sedation, and hypotension. Educate patients on the risks and advise against operating heavy machinery or driving.
Patients may experience profound sedation, respiratory depression, hypotension, and impaired psychomotor function. This can lead to an increased risk of falls, accidental injury, and potentially life-threatening respiratory arrest. The combination significantly impairs the ability to operate machinery or drive safely.
Mechanism
Oxycodone, an opioid agonist, and carisoprodol, a centrally acting muscle relaxant, both exert significant central nervous system (CNS) depressant effects. Carisoprodol is metabolized to meprobamate, which also possesses sedative and anxiolytic properties, further contributing to CNS depression. The co-administration of these agents results in an additive depressant effect on the CNS.
Clinical Management
Concomitant use should generally be avoided due to the high risk of severe adverse effects. If co-administration is deemed absolutely necessary, initiate both medications at the lowest effective doses and titrate slowly, with close monitoring for signs of CNS and respiratory depression. Educate patients on the risks and advise against driving or operating heavy machinery.
Patients may experience severe sedation, profound respiratory depression, coma, and even death. Other clinical effects include dizziness, confusion, impaired psychomotor function, and hypotension. The risk is heightened due to carisoprodol's metabolism to meprobamate, which significantly contributes to CNS depression.
Mechanism
Morphine is an opioid agonist that causes central nervous system (CNS) depression by binding to mu-opioid receptors. Carisoprodol is a centrally acting skeletal muscle relaxant that also produces CNS depression, partly through its active metabolite meprobamate, which has anxiolytic and sedative properties. The co-administration of these agents results in an additive depressant effect on the CNS.
Clinical Management
Avoid concomitant use of morphine and carisoprodol whenever possible. If co-administration is unavoidable, initiate with the lowest effective doses of both drugs and titrate carefully, monitoring closely for signs of respiratory depression and sedation. Educate patients about the risks and advise against operating heavy machinery or driving. Consider alternative non-opioid analgesics or non-benzodiazepine muscle relaxants.
Patients may experience profound sedation, dizziness, confusion, and psychomotor impairment. There is an increased risk of respiratory depression, which can be life-threatening, and hypotension. Impaired motor function can lead to an increased risk of falls and accidents.
Mechanism
Both tramadol and carisoprodol are central nervous system (CNS) depressants. Tramadol exerts its analgesic effects primarily through mu-opioid receptor agonism and inhibition of norepinephrine and serotonin reuptake. Carisoprodol is a centrally acting skeletal muscle relaxant that is metabolized to meprobamate, a Schedule IV controlled substance with anxiolytic and sedative properties. The concomitant use leads to an additive depressant effect on the CNS.
Clinical Management
Avoid concomitant use of tramadol and carisoprodol due to the significant risk of additive CNS depression. If co-administration is unavoidable, reduce the dosage of one or both drugs, monitor patients closely for signs of respiratory depression and sedation, and educate them on the risks. Consider alternative non-opioid analgesics or non-benzodiazepine muscle relaxants.
Patients may experience profound sedation, dizziness, confusion, psychomotor impairment, and respiratory depression, which can be life-threatening. The risk of falls, accidents, and overdose is significantly increased due to the synergistic CNS depression.
Mechanism
Both codeine, an opioid analgesic, and carisoprodol, a centrally acting muscle relaxant, exert their primary effects through central nervous system (CNS) depression. Carisoprodol is metabolized to meprobamate, which also possesses significant CNS depressant and anxiolytic properties. This combination results in an additive depressant effect on the CNS.
Clinical Management
Concomitant use should generally be avoided. If co-administration is unavoidable, reduce the dosage of one or both drugs, initiate at the lowest effective dose, and monitor closely for signs of respiratory depression and sedation. Educate patients about the risks and advise against driving or operating heavy machinery.
Patients may experience profound sedation, respiratory depression, hypotension, psychomotor impairment, and coma. The combination significantly increases the risk of accidental overdose and death. Impaired motor function can also lead to an increased risk of falls and injuries.
Mechanism
Both methadone, an opioid agonist, and carisoprodol, a centrally acting skeletal muscle relaxant, cause central nervous system (CNS) depression. Carisoprodol is metabolized to meprobamate, which is a Schedule IV controlled substance with anxiolytic and sedative properties, further contributing to CNS depression. This additive pharmacological effect leads to an increased risk of severe adverse outcomes.
Clinical Management
Concomitant use should generally be avoided due to the high risk of severe adverse effects. If co-administration is unavoidable, initiate both medications at the lowest effective doses and titrate slowly, monitoring closely for signs of respiratory depression and sedation. Educate patients and caregivers on the risks and symptoms of CNS depression and respiratory compromise.
Patients are at significantly increased risk for profound sedation, respiratory depression, coma, and even death. Other clinical effects include dizziness, impaired psychomotor function, and hypotension. The risk is heightened by carisoprodol's active metabolite, meprobamate, which also contributes to CNS depression.
Mechanism
Hydromorphone, an opioid agonist, primarily exerts its effects through mu-opioid receptors, leading to central nervous system (CNS) depression. Carisoprodol, a centrally acting muscle relaxant, is metabolized to meprobamate, which has anxiolytic and sedative properties through GABA-A receptor potentiation. The co-administration results in additive CNS depressant effects.
Clinical Management
Concomitant use should generally be avoided due to the high risk of severe adverse effects. If co-administration is unavoidable, initiate with the lowest effective doses of both medications and monitor patients closely for signs of respiratory depression and sedation. Consider alternative non-opioid analgesics or non-benzodiazepine muscle relaxants.
The combined CNS depressant effects can lead to profound sedation, respiratory depression, hypotension, psychomotor impairment, and coma. Patients may experience dizziness, confusion, decreased level of consciousness, and impaired coordination, significantly increasing the risk of falls and accidental injury. The risk of life-threatening respiratory depression is particularly elevated.
Mechanism
Oxymorphone, an opioid agonist, produces central nervous system (CNS) depression by binding to mu-opioid receptors. Carisoprodol, a centrally acting skeletal muscle relaxant, also causes CNS depression, primarily through its active metabolite meprobamate, which acts as a GABA-A receptor positive allosteric modulator. The co-administration of these agents results in an additive depressant effect on the CNS.
Clinical Management
Concomitant use of oxymorphone and carisoprodol should generally be avoided due to the high risk of severe CNS and respiratory depression. If co-administration is unavoidable, the lowest effective doses of both drugs should be used, and patients must be closely monitored for signs of respiratory depression and excessive sedation. Consider alternative muscle relaxants with less CNS depressant activity or non-opioid analgesics.
Patients may experience profound sedation, respiratory depression, hypotension, and psychomotor impairment, increasing the risk of falls and accidental injury. The combination can also lead to coma and death, particularly with higher doses or in vulnerable populations.
Mechanism
Tapentadol is a centrally acting analgesic with opioid agonist activity and norepinephrine reuptake inhibition. Carisoprodol is a centrally acting muscle relaxant that is metabolized to meprobamate, a Schedule IV controlled substance with anxiolytic and sedative properties. The co-administration of these agents leads to additive central nervous system (CNS) depression by enhancing GABAergic activity and opioid receptor agonism, respectively.
Clinical Management
Avoid concomitant use of tapentadol and carisoprodol due to the high risk of severe additive CNS depression. If co-administration is unavoidable, reduce the dosage of one or both drugs, closely monitor for signs of respiratory depression and sedation, and educate the patient on the risks. Consider alternative non-opioid analgesics or non-benzodiazepine muscle relaxants.
For complete prescribing information:
View full CARISOPRODOL monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.